GBM
MCID: GLB015
MIFTS: 63

Glioblastoma Multiforme (GBM) malady

Categories: Cancer diseases

Aliases & Classifications for Glioblastoma Multiforme

Aliases & Descriptions for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 52 14 69
Glioblastoma 42 69
Gbm 12 14
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 69
Adult Glioblastoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3068
MeSH 42 D005909

Summaries for Glioblastoma Multiforme

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to brain glioblastoma multiforme and adult spinal cord glioblastoma multiforme, and has symptoms including headache and seizures. An important gene associated with Glioblastoma Multiforme is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Avastin and Gliadel Wafer have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and lung, and related phenotypes are Decreased viability and endocrine/exocrine gland

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
id Related Disease Score Top Affiliating Genes
1 brain glioblastoma multiforme 12.3
2 adult spinal cord glioblastoma multiforme 12.1
3 glioblastoma 12.1
4 goodpasture syndrome 11.8
5 glioma susceptibility 1 11.8
6 giant cell glioblastoma 11.4
7 glioma susceptibility 9 11.0
8 glioblastoma classical subtype 11.0
9 glioma susceptibility 2 11.0
10 glioblastoma proneural subtype 11.0
11 glioblastoma mesenchymal subtype 11.0
12 glioblastoma 3 11.0
13 glioblastoma neural subtype 11.0
14 mismatch repair cancer syndrome 11.0
15 astrocytoma 10.5
16 paternal uniparental disomy of chromosome 1 10.4 EGFR PDGFRA TP53
17 childhood embryonal testis carcinoma 10.4 EGFR PTEN TP53
18 acute canaliculitis 10.4 CDKN2A MTOR
19 rommen mueller sybert syndrome 10.4 CDK4 MDM2 TP53
20 fragile x-associated tremor/ataxia syndrome 10.4 CDKN2A PDGFRA TP53
21 clear cell adenofibroma 10.4 CDKN2A TP53
22 wolffian adnexal neoplasm 10.4 EGFR TP53
23 tricuspid valve prolapse 10.4 CDKN2A EGFR PDGFRA
24 spastic paraplegia 1 10.4 EGFR MDM2 TP53
25 chronic monocytic leukemia 10.4 CDKN2A EGFR TP53
26 urethral verrucous carcinoma 10.4 CDKN2A PTEN TP53
27 fallopian tube benign neoplasm 10.4 EGFR MGMT TP53
28 mediastinum synovial sarcoma 10.4 MTOR PDGFRA TP53
29 thymus squamous cell carcinoma 10.4 CDKN2A EGFR TP53
30 secondary hyperparathyroidism of renal origin 10.4 CDKN2A EGFR TP53
31 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53
32 brain stem angioblastoma 10.4 CDK4 MDM2 TP53
33 small intestinal sarcoma 10.4 MDM2 PDGFRA PTEN
34 hemorrhagic proctocolitis 10.4 AKT3 MTOR MYC
35 benign ependymoma 10.4 EGFR PDGFRA TP53
36 aortic aneurysm 10.4 CDK4 CDKN2A MDM2
37 ossifying fibromyxoid tumor 10.4 CDK4 CDKN2A TP53
38 allergic contact dermatitis 10.4 CDKN2A EGFR TP53
39 acute mountain sickness 10.4 CDKN1A MDM2 TP53
40 episodic ataxia 10.3 CDK4 CDKN2A MDM2
41 myxedema 10.3 CDKN2A EGFR PTEN TP53
42 estrogen-receptor positive breast cancer 10.3 CDKN2A EGFR TP53
43 glioma 10.3
44 pityriasis rosea 10.3 CDKN2A EGFR TP53
45 sengers syndrome 10.3 CDKN2A EGFR PDGFRA PTEN
46 prostatic adenoma 10.3 CDKN2A EGFR PTEN TP53
47 scarlet fever 10.3 CDKN1A MDM2 TP53
48 vascular myelopathy 10.3 CDKN2A MDM2 TP53
49 enchondromatosis dwarfism deafness 10.3 CDK4 MDM2 TP53
50 mood disorder 10.3 MTOR MYC RB1

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

UMLS symptoms related to Glioblastoma Multiforme:


headache, seizures

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.08 MTOR EGFR
2 Decreased viability GR00173-A 11.08 PDGFRA
3 Decreased viability GR00221-A-1 11.08 CDKN2A PTK2 MYC PDGFRA PDGFRB AKT1
4 Decreased viability GR00221-A-2 11.08 AKT1 AKT3 CDK2 CDK6
5 Decreased viability GR00221-A-3 11.08 PDGFRB CDKN2A MYC PDGFRA AKT1 AKT3
6 Decreased viability GR00221-A-4 11.08 CDKN2A PTK2 PDGFRA PDGFRB AKT1 MTOR
7 Decreased viability GR00301-A 11.08 CDK2 AKT3 CDK6
8 Decreased viability GR00342-S-1 11.08 PDGFRB MTOR
9 Decreased viability GR00342-S-2 11.08 MTOR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.43 MTOR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.43 AKT3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.43 MTOR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.43 CDK4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.43 EGFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.43 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.43 AKT3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.43 CDK6
18 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.43 CDK6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.43 MTOR AKT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.43 CDK6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.43 AKT3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.43 CDK6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.43 CDK6 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.43 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.43 EGFR CDK4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.43 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.43 CDK6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.43 AKT3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.43 MTOR CDK4 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.43 EGFR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.43 CDK4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.43 AKT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.43 AKT3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.43 AKT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.43 MTOR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.43 AKT1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.43 MTOR CDK4 CDK6 EGFR AKT1 AKT3
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.41 CDK6 MYC
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.41 CDK6
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.41 MYC
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.41 MTOR MYC
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.41 CDK6
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.41 AKT1
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.41 MYC
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.41 MTOR
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.41 AKT3 CDK6 MTOR MYC AKT1
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.41 CDK6
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.41 CDK6 AKT3
49 Decreased substrate adherent cell growth GR00193-A-1 10.25 CDK2 CDK6
50 Decreased substrate adherent cell growth GR00193-A-2 10.25 AKT3 CDK2 CDK4 CDK6 EGFR MTOR
51 Decreased substrate adherent cell growth GR00193-A-3 10.25 AKT3 CDK2 CDK4
52 Decreased substrate adherent cell growth GR00193-A-4 10.25 CDK2 CDK4
53 Decreased viability with paclitaxel GR00179-A-1 10.11 EGFR MTOR PTK2
54 Decreased viability with paclitaxel GR00179-A-2 10.11 MTOR
55 Decreased viability with paclitaxel GR00179-A-3 10.11 MTOR EGFR
56 Decreased cell migration GR00055-A-1 9.99 AKT1 AKT3 CDK4 EGFR MTOR PDGFRB
57 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.97 AKT3 CDK4 EGFR MTOR PDGFRB PTEN
58 Increased cell death HMECs cells GR00103-A-0 9.87 CDK2 EGFR MDM2 MYC PDGFRB PTEN
59 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.84 RB1 PTEN TP53 PTK2 AKT1 CDK2
60 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.84 PTEN TP53 PTK2 RB1 AKT1 CDK2
61 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 9.78 CDK2 CDK4 EGFR PTK2
62 Increased cell viability after pRB stimulation GR00230-A-1 9.73 AKT1 AKT3 CDK2 CDK4 EGFR PDGFRB
63 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 CDK2 CDKN1A MDM2 MGMT PTK2 TP53

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.57 CDKN2A EGF EGFR MDM2 MGMT MTOR
2 cardiovascular system MP:0005385 10.55 AKT1 AKT3 CDK2 CDK4 CDK6 CDKN1A
3 cellular MP:0005384 10.55 TP53 AKT1 AKT3 CDK2 CDK4 CDK6
4 growth/size/body region MP:0005378 10.54 CDK2 CDK4 CDK6 CDKN1A CDKN2A EGF
5 immune system MP:0005387 10.54 PDGFRB PTEN PTK2 RB1 TP53 CDK6
6 hematopoietic system MP:0005397 10.53 CDK2 CDK4 CDK6 CDKN1A CDKN2A EGFR
7 homeostasis/metabolism MP:0005376 10.52 MYC PDGFRA PDGFRB PTEN PTK2 RB1
8 embryo MP:0005380 10.5 EGFR MDM2 MTOR MYC PDGFRA PDGFRB
9 behavior/neurological MP:0005386 10.47 CDKN2A GPNMB MDM2 MTOR MYC PDGFRA
10 mortality/aging MP:0010768 10.46 EGFR MDM2 MGMT MTOR MYC PDGFRA
11 digestive/alimentary MP:0005381 10.42 CDK4 CDKN1A CDKN2A EGF EGFR MDM2
12 integument MP:0010771 10.42 PTK2 RB1 TP53 AKT1 CDK2 CDK4
13 neoplasm MP:0002006 10.41 TP53 AKT1 AKT3 CDK2 CDK4 CDK6
14 muscle MP:0005369 10.4 AKT1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
15 nervous system MP:0003631 10.36 AKT1 AKT3 CDK4 CDKN1A CDKN2A EGFR
16 liver/biliary system MP:0005370 10.34 AKT1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
17 adipose tissue MP:0005375 10.29 AKT1 CDKN1A EGFR MTOR MYC PDGFRB
18 normal MP:0002873 10.25 AKT1 AKT3 CDK4 EGF EGFR MDM2
19 limbs/digits/tail MP:0005371 10.24 CDKN1A EGFR MDM2 MYC PDGFRA PDGFRB
20 craniofacial MP:0005382 10.21 CDKN1A EGFR MDM2 MYC PDGFRA PDGFRB
21 reproductive system MP:0005389 10.19 AKT1 AKT3 CDK2 CDK4 CDK6 CDKN1A
22 no phenotypic analysis MP:0003012 10.13 TP53 CDKN1A CDKN2A EGFR MDM2 MGMT
23 pigmentation MP:0001186 10.07 CDK4 CDKN2A EGFR GPNMB MDM2 MYC
24 renal/urinary system MP:0005367 10.02 CDK4 CDKN1A EGFR MDM2 MTOR PDGFRA
25 respiratory system MP:0005388 9.9 CDKN1A CDKN2A EGFR MGMT MTOR PDGFRA
26 skeleton MP:0005390 9.73 AKT1 CDKN1A CDKN2A EGFR MDM2 MTOR
27 vision/eye MP:0005391 9.36 RB1 TP53 CDK2 CDK4 CDKN1A CDKN2A

Drugs & Therapeutics for Glioblastoma Multiforme

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Avastin 17 46 BEVACIZUMAB Genentech Approved July 2009
2
Gliadel Wafer 17 46 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals Approved February 1997
3
Temodar 17 46 TEMOZOLOMIDE Schering-Plough Approved August 1999

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 574)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
8
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
9
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
10
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
11
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
12
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
13
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
14
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
15
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
17
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
18
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
19
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
20
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
21
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
22
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
23
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
24
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
25
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
26
chloroquine Approved, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
27
Morphine Approved, Investigational Phase 3 57-27-2 5288826
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
30
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
31
Copper Approved Phase 2, Phase 3,Phase 1,Early Phase 1 15158-11-9, 7440-50-8 27099
32
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
33
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
34
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
37
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
38
Flucytosine Approved Phase 2, Phase 3,Phase 1 2022-85-7 3366
39
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
40
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
41
Losartan Approved Phase 3 114798-26-4 3961
42
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
43
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
44
Norepinephrine Approved Phase 3 51-41-2 439260
45
Cyproheptadine Approved Phase 3 129-03-3 2913
46
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
47
Vitamin C Approved, Nutraceutical Phase 3,Phase 2,Phase 1 50-81-7 5785 54670067
48
Camptothecin Experimental Phase 2, Phase 3,Phase 1 7689-03-4
49
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
50
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 1203)
id Name Status NCT ID Phase
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
3 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
4 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
8 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
9 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
10 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3
11 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
12 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3
13 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3
14 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3
15 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3
16 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3
17 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
18 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3
19 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
20 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3
21 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
22 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
23 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3
24 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3
25 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3
26 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3
27 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3
28 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3
29 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
30 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
31 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
32 A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3
33 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
34 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
35 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
36 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
37 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
38 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
39 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
40 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
41 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3
42 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma Recruiting NCT02546102 Phase 3
43 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Recruiting NCT01507506 Phase 3
44 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3
45 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3
46 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02617589 Phase 3
47 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3
48 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3
49 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
50 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Active, not recruiting NCT02511405 Phase 3

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

39
Brain, Endothelial, Lung, Colon, Bone, T Cells, Spinal Cord

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 781)
id Title Authors Year
1
A continuous-infusion dynamic MRI model at 3.0 Tesla for the serial quantitative evaluation of microvascular proliferation in an animal model of glioblastoma multiforme. ( 28078795 )
2017
2
Advances in the targeting of HIF-1I+ and future therapeutic strategies for glioblastoma multiforme (Review). ( 27959421 )
2017
3
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells. ( 28035389 )
2017
4
IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status. ( 28098764 )
2017
5
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. ( 28011470 )
2017
6
Knockdown of Ras-Related Protein 25 (Rab25) Inhibits the In Vitro Cytotoxicity and In Vivo Antitumor Activity of Human Glioblastoma Multiforme Cells. ( 28281975 )
2017
7
UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy. ( 27593939 )
2016
8
LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis. ( 27604987 )
2016
9
Hypervascular glioblastoma multiforme or arteriovenous malformation associated Glioma? A diagnostic and therapeutic challenge: A case report. ( 27999714 )
2016
10
Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. ( 27672648 )
2016
11
Patterns of Failure for Pediatric Glioblastoma Multiforme Following Radiation Therapy. ( 27128519 )
2016
12
Rapid Neurological Recovery Following Partial Surgical Resection of Spinal Glioblastoma Multiforme in a Pediatric Patient Presenting With Complete Paraplegia. ( 27403775 )
2016
13
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells. ( 26902608 )
2016
14
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( 28011886 )
2016
15
Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin. ( 26646311 )
2016
16
Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme. ( 27105898 )
2016
17
Prognostic value of relative cerebral blood volume (rCBV) in patients with recurrent glioblastoma multiforme treated with bevacizumab. ( 27603407 )
2016
18
Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme. ( 27584787 )
2016
19
Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report. ( 27449352 )
2016
20
Anti-proliferative and anti-migration effects of Polish propolis combined with Hypericum perforatum L. on glioblastoma multiforme cell line U87MG. ( 27647142 )
2016
21
War on Glioblastoma Multiforme: 2-Pronged Siege on Glutamine. ( 27133092 )
2016
22
Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme. ( 27172136 )
2016
23
Methylglyoxal (MGO) inhibits proliferation and induces cell death of human glioblastoma multiforme T98G and U87MG cells. ( 27133062 )
2016
24
Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors. ( 27593971 )
2016
25
Cancer Stem Cells in Glioblastoma Multiforme. ( 27617262 )
2016
26
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
27
Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiforme cells in vitro. ( 25620587 )
2016
28
Congenital Glioblastoma multiforme and eruptive disseminated Spitz nevi. ( 27180150 )
2016
29
Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. ( 27595933 )
2016
30
Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis. ( 27923049 )
2016
31
Primitive Neuroectodermal Tumor with Glioblastoma Multiforme Components in an Adult: A Collision Tumor. ( 26918224 )
2016
32
SU-F-T-392: Superior Brainstem and Cochlea Sparing with VMAT for Glioblastoma Multiforme. ( 28046578 )
2016
33
MET Expressed in Glioma Stem Cells Is a Potent Therapeutic Target for Glioblastoma Multiforme. ( 27354625 )
2016
34
Immune phenotypes predict survival in patients with glioblastoma multiforme. ( 27585656 )
2016
35
Label-free detection of fibrillar collagen deposition associated with vascular elements in glioblastoma multiforme by using multiphoton microscopy. ( 27643398 )
2016
36
Symptomatic spinal metastasis from intracranial glioblastoma multiforme - Two illustrative cases and a review of the literature. ( 27174685 )
2016
37
MiR-153 as a Tumor Suppressor in Glioblastoma Multiforme is Downregulated by DNA Methylation. ( 27215075 )
2016
38
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. ( 27148537 )
2016
39
Aligned Nanotopography Promotes a Migratory State in Glioblastoma Multiforme Tumor Cells. ( 27189099 )
2016
40
Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy. ( 27903197 )
2016
41
A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme. ( 27597932 )
2016
42
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. ( 27170523 )
2016
43
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature". ( 28032144 )
2016
44
Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth. ( 27602106 )
2016
45
Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. ( 27619250 )
2016
46
c-MYC inhibition impairs hypoxia response in glioblastoma multiforme. ( 27119353 )
2016
47
Delayed Diagnosis of Glioblastoma Multiforme Presenting With Atypical Psychiatric Symptoms. ( 28033459 )
2016
48
CD4(+)Foxp3(-) type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages. ( 27644153 )
2016
49
SU-F-R-03: Classification of Glioblastoma Multiforme Molecular Subtypes Using Three-Dimensional Multi-Modal MR Imaging Features. ( 28046940 )
2016
50
Dysregulation of TFDP1 and of the cell cycle pathway in high-grade glioblastoma multiforme: a bioinformatic analysis. ( 27323154 )
2016

Variations for Glioblastoma Multiforme

ClinVar genetic disease variations for Glioblastoma Multiforme:

6 (show top 50) (show all 62)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh37 Chromosome 10, 89717672: 89717672
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
9 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
14 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
17 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
20 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
23 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
24 EGFR NM_005228.4(EGFR): c.2155G> T (p.Gly719Cys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
25 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
26 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
27 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic/Likely pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
28 EGFR NM_005228.4(EGFR): c.2156G> C (p.Gly719Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913428 GRCh37 Chromosome 7, 55241708: 55241708
29 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
30 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
31 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
32 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
33 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
34 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
35 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
36 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
37 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
38 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
39 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
40 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
41 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
42 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
43 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
44 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
45 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
46 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
47 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
48 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
49 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
50 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000 Gain Glioblastoma multiforme
30 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
31 25428 1 189000000 197500000 Gain Glioblastoma multiforme
32 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
33 26137 1 197500000 205300000 Amplification LRRN5 Glioblastoma multiforme
34 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
35 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
37 26146 1 197500000 205300000 Amplificationlication HDMX Glioblastoma multiforme
38 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
39 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
40 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
41 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
42 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
43 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
44 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
45 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
46 31747 1 30500000 171200000 Gain Glioblastoma multiforme
47 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
48 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
49 32900 1 4028404 6333694 Deletion CHD5 Glioblastoma multiforme
50 33876 1 4952248 20897624 Deletion CDC42 Glioblastoma multiforme

Expression for Glioblastoma Multiforme

Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for Glioblastoma Multiforme